Fosaprepitant Dimeglumine is an antiemetic medication approved by the U.S. FDA on January 25, 2008. It is used in combination with other medicines to prevent nausea and vomiting caused by certain types of chemotherapy, including highly and moderately emetogenic cancer treatments. Fosaprepitant is a prodrug of aprepitant, meaning it converts into the active form (aprepitant) after administration.

Fosaprepitant Dimeglumine is mainly used to prevent nausea and vomiting caused by chemotherapy, especially the strong types that are more likely to upset your stomach.

When you're going through cancer treatment, feeling sick or throwing up can make things even harder. This medicine helps stop that from happening, so you can feel a bit more comfortable during your treatment.

Fosaprepitant Dimeglumine is administered intravenously (IV) by a healthcare provider.

• Standard dose: 150 mg given as a single IV infusion over 20 to 30 minutes, about 30 minutes before chemotherapy.

• The dosage and duration will be decided by your doctor based on your age, weight, and treatment type.

Common side effects:

• Headache

• Fatigue

• Constipation

• Indigestion

• Loss of appetite

• Hiccups

Serious side effects (Seek immediate help):

• Allergic reactions (rash, itching, swelling, skin peeling)

• Breathing difficulties

• Trouble swallowing

• Severe skin reactions at the injection site

Before taking this medication, you need to inform your doctor if you have liver disorders, allergic conditions, or other diseases. Indigestion, tiredness, headache, and loss of appetite are the common side effects of fosaprepitant dimeglumine injection.

Inform your doctor if you are allergic to fosaprepitant dimeglumine or any of the ingredients present in them or have kidney or muscle disorder. Inform your doctor about your prescribed and non-prescribed medicine and take a proper diet while under medication. It will be helpful for him to treat you based on your previous medical or make some dose adjustments.

This injection should be administered only by the doctor or nurse and do not self administer this injection. Inform the doctor if the patient has any history of allergic reactions, liver, or kidney problems, and other medication taken for different medical conditions. Consult the doctor if the patient is planning for pregnancy or breastfeeding mother before taking this medication. Avoid driving and handling heavy machinery as it causes dizziness. Patients may feel a lack of concentration and alertness.

1. KD Tripathi, Essentials of Medical Pharmacology, Antiemetic, Prokinetic and Digestant Drugs, 7th edition, 2013, 669-670.
2. Merck Sharp & Dohme Corp, US Food and Drug Administration, [Revised date Feb 2016], [Accessed date 29th Nov 2021, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022023s014lbl.pdf
3. .Merck Sharp & Dome BV, European Medicines Compendium (emc), [Revised date May 2021], [Accessed date 29th Nov 2021], https://www.medicines.org.uk/emc/files/pil.5947.pdf

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.